Cell Migration Profile of Triple-Negative Breast Cancer Cells Treated with a Combination of a PARP Inhibitor and Calcitriol

Introduction: In metastasis, cell migration is critical. One of the most aggressive kinds of breast cancer is triple-negative breast cancer (TNBC). TNBC monotherapy is frequently ineffective because of the presence of innate and acquired resistance, and likely, combining two or more drugs with diffe...

Full description

Saved in:
Bibliographic Details
Published inAsia-Pacific journal of molecular biology and biotechnology Vol. 30; p. 32
Main Authors Wong, Fu Hou, Vijayarajkumar, Palanirajan, Ng, Edmond Siah Chye, Keat, Tan Chung, Amini, Farahnaz
Format Journal Article
LanguageEnglish
Published Kuala Lumpur Malaysian Society for Molecular Biology and Biotechnology 01.06.2022
Subjects
25-Hydroxyvitamin D
Breast cancer
Calcitriol
Cancer therapies
Cell adhesion & migration
Cell migration
Combined treatment
Cytotoxicity
Drugs
Inhibitors
Metastases
Metastasis
Poly(ADP-ribose) polymerase
Statistical analysis
Toxicity
Online AccessGet full text

Cover

More Information
Summary:Introduction: In metastasis, cell migration is critical. One of the most aggressive kinds of breast cancer is triple-negative breast cancer (TNBC). TNBC monotherapy is frequently ineffective because of the presence of innate and acquired resistance, and likely, combining two or more drugs with different mechanisms of action is more effective. This study was aimed to assess the cell migration profile of TNBC cell lines treated with a combination of PARP inhibitor (talazoparib) and calcitriol compared to the monotherapy of each drug. Methods: The cytotoxicity effect of calcitriol, talazoparib and their combination were determined using xCELLigene real-time cell analysis in BT-20 and MDA-MB-468 cell lines. The IC50 concentration of both drugs was determined and used to assess the cell migration rate using the CIM-Plate assay. Results: The IC50 values of talazoparib were ten times higher in MDA-MB-468 compared to BT-20. In BT-20: i. Calcitriol alone slightly lessened cell migration compared with the control (untreated) (8.28% lesser), ii. The combined treatment of talazoparib and calcitriol (both at IC50 concentration) significantly decreased the migration rate compared with the control (39% lower) (P <0.05). iii. Talazoparib monotherapy after 24 hours enhanced the cell migration but was not statistically significant. In MDA-MB-468, all treatments significantly reduced cell migration. Conclusion: MDA-MB-486 was more resistant to talazoparib treatment. Talazoparib monotherapy enhanced cell migration in BT-20 but decreased the cell migration in MDA-MB-468. The combined therapy enhanced the migration inhibitory effect in both cell lines. Calcitriol monotherapy might be an adjuvant therapy to overcome metastasis in some cases.
ISSN:0128-7451